Streamlined Antibacterial Development Would Not Be Limited To First-In-Disease Products, FDA Says
This article was originally published in The Pink Sheet Daily
Executive Summary
A second product in a particular disease could still be considered as meeting an unmet need in certain circumstances, according to new draft guidance.